Behind the Paper
The real stories behind the latest research papers, from conception to publication, the highs and the lows
A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent anti-tumor response
The type 1 NKT cell stimulating glycolipid α-galactosylceramide (α-GalCer) was first identified by the Pharmaceutical Research Laboratory of Kirin Brewery in a screen for novel anti-tumor agents. Based on promising preclinical data it was tested as an anticancer drug in multiple clinical studies.
New players against AML: novel targets with preclinical potencies
Better understanding of AML biology and survival tactics has facilitated a wave of newly approved drugs against AML and also revealed a range of targets to be exploited for treatment. In our review, we discuss what these new targets are and how targeting them in combination might be beneficial.
The story behind the SAVI project
A computer-generated database of a billion+ easily synthesizable molecules aimed at drug design
After the Paper: A new life beyond academia
I recently swapped a career in biochemistry for one in the conservation of Nature, In this ‘After the Paper’ blog I summarise some of the background to my journey from the nanometre scale to the macro scale and some current goals and ambitions.
